{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T21:11:05Z","timestamp":1761340265715,"version":"3.44.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,20]]},"DOI":"10.7759\/cureus.90619","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:32:06Z","timestamp":1755736326000},"source":"Crossref","is-referenced-by-count":1,"title":["Rucaparib-Associated Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome"],"prefix":"10.7759","author":[{"given":"Steven","family":"Ludlow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bushra","family":"Shariff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misbahuddin","family":"Syed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsi.2013.09.006","article-title":"Drug reaction with eosinophilia and systemic symptoms: a drug-induced hypersensitivity syndrome with variable clinical features","volume":"31","author":"Chen YC","year":"2013","unstructured":"Chen YC, Cho YT, Chang CY, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a drug-induced hypersensitivity syndrome with variable clinical features. Dermatol Sin. 2013, 31:196-204. 10.1016\/j.dsi.2013.09.006","journal-title":"Dermatol Sin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.67783","article-title":"A drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome manifestation in tubercular cervical lymphadenopathy: a case report","volume":"16","author":"Bagrecha M","year":"2024","unstructured":"Bagrecha M, Balamoni V, Ganta SV. A drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome manifestation in tubercular cervical lymphadenopathy: a case report. Cureus. 2024, 16:e67783. 10.7759\/cureus.67783","journal-title":"Cureus"},{"key":"ref3","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome","volume":"6","author":"Choudhary S","year":"2013","unstructured":"Choudhary S, McLeod M, Torchia D, Romanelli P. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. J Clin Aesthet Dermatol. 2013, 6:31-7.","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1222","article-title":"Six-year retrospective review of drug reaction with eosinophilia and systemic symptoms","volume":"92","author":"Wongkitisophon P","year":"2012","unstructured":"Wongkitisophon P, Chanprapaph K, Rattanakaemakorn P, Vachiramon V. Six-year retrospective review of drug reaction with eosinophilia and systemic symptoms. Acta Derm Venereol. 2012, 92:200-5. 10.2340\/00015555-1222","journal-title":"Acta Derm Venereol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.01.017","article-title":"The DRESS syndrome: a literature review","volume":"124","author":"Cacoub P","year":"2011","unstructured":"Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, Roujeau JC. The DRESS syndrome: a literature review. Am J Med. 2011, 124:588-97. 10.1016\/j.amjmed.2011.01.017","journal-title":"Am J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/269501","article-title":"Dress syndrome due to nevirapine treated with methylprednisolone","volume":"2013","author":"Pott Junior H","year":"2013","unstructured":"Pott Junior H, Gosuen GC, Gales AC. Dress syndrome due to nevirapine treated with methylprednisolone. Case Rep Med. 2013, 2013:269501. 10.1155\/2013\/269501","journal-title":"Case Rep Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000326","article-title":"Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome","volume":"27","author":"Mirza S","year":"2017","unstructured":"Mirza S, Hill E, Ludlow SP, Nanjappa S. Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome. Melanoma Res. 2017, 27:271-3. 10.1097\/CMR.0000000000000326","journal-title":"Melanoma Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2023.101211","article-title":"Rucaparib for PARP inhibitor-pretreated ovarian cancer: a GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program","volume":"48","author":"Yubero A","year":"2023","unstructured":"Yubero A, Est\u00e9vez P, Barqu\u00edn A, et al.. Rucaparib for PARP inhibitor-pretreated ovarian cancer: a GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program. Gynecol Oncol Rep. 2023, 48:101211. 10.1016\/j.gore.2023.101211","journal-title":"Gynecol Oncol Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0229","article-title":"Real-world delivery of rucaparib to patients with ovarian cancer: recommendations based on an integrated safety analysis of ARIEL2 and Study 10","volume":"25","author":"Drew Y","year":"2020","unstructured":"Drew Y, Kristeleit RS, Oaknin A, Ray-Coquard I, Haris NM, Swisher EM. Real-world delivery of rucaparib to patients with ovarian cancer: recommendations based on an integrated safety analysis of ARIEL2 and Study 10. Oncologist. 2020, 25:e109-19. 10.1634\/theoncologist.2019-0229","journal-title":"Oncologist"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.02.039","article-title":"PARP inhibitors in ovarian cancer: current status and future promise","volume":"133","author":"Liu JF","year":"2014","unstructured":"Liu JF, Konstantinopoulos PA, Matulonis UA. PARP inhibitors in ovarian cancer: current status and future promise. Gynecol Oncol. 2014, 133:362-9. 10.1016\/j.ygyno.2014.02.039","journal-title":"Gynecol Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2018.10.008","article-title":"PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper","volume":"10","author":"Liposits G","year":"2019","unstructured":"Liposits G, Loh KP, Soto-Perez-de-Celis E, et al.. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper. J Geriatr Oncol. 2019, 10:337-45. 10.1016\/j.jgo.2018.10.008","journal-title":"J Geriatr Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02788.x","article-title":"Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation","volume":"9","author":"Mennicke M","year":"2009","unstructured":"Mennicke M, Zawodniak A, Keller M, et al.. Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation. Am J Transplant. 2009, 9:2197-202. 10.1111\/j.1600-6143.2009.02788.x","journal-title":"Am J Transplant"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)31663-1","article-title":"Severe acute hepatitis in the DRESS syndrome: report of two cases","volume":"9","author":"Lens S","year":"2010","unstructured":"Lens S, Crespo G, Carri\u00f3n J, Miquel R, Navasa M. Severe acute hepatitis in the DRESS syndrome: report of two cases. Ann Hepatol. 2010, 9:198-201. 10.1016\/S1665-2681(19)31663-1","journal-title":"Ann Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.idoj_196_21","article-title":"RegiSCAR DRESS (drug reaction with eosinophilia and systemic symptoms) validation scoring system and Japanese consensus group criteria for atypical drug-induced hypersensitivity syndrome (DIHS): a comparative analysis","volume":"13","author":"Sasidharanpillai S","year":"2022","unstructured":"Sasidharanpillai S, Ajithkumar K, Jishna P, Khader A, Anagha KV, Binitha MP, Chathoth AT. RegiSCAR DRESS (drug reaction with eosinophilia and systemic symptoms) validation scoring system and Japanese consensus group criteria for atypical drug-induced hypersensitivity syndrome (DIHS): a comparative analysis. Indian Dermatol Online J. 2022, 13:40-5. 10.4103\/idoj.idoj_196_21","journal-title":"Indian Dermatol Online J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/344053-rucaparib-associated-drug-reaction-with-eosinophilia-and-systemic-symptoms-syndrome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:32:07Z","timestamp":1755736327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/344053-rucaparib-associated-drug-reaction-with-eosinophilia-and-systemic-symptoms-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.90619","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,8,20]]}}}